297 related articles for article (PubMed ID: 28594074)
1. Testosterone and dihydrotestosterone levels in the transition zone correlate with prostate volume.
Pejčić T; Tosti T; Tešić Ž; Milković B; Dragičević D; Kozomara M; Čekerevac M; Džamić Z
Prostate; 2017 Jul; 77(10):1082-1092. PubMed ID: 28594074
[TBL] [Abstract][Full Text] [Related]
2. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
Habib FK; Ross M; Tate R; Chisholm GD
Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
[TBL] [Abstract][Full Text] [Related]
3. Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer.
van der Sluis TM; Vis AN; van Moorselaar RJ; Bui HN; Blankenstein MA; Meuleman EJ; Heijboer AC
BJU Int; 2012 Jan; 109(2):176-82. PubMed ID: 21992222
[TBL] [Abstract][Full Text] [Related]
4. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.
Miyoshi Y; Uemura H; Suzuki K; Shibata Y; Honma S; Harada M; Kubota Y
Andrology; 2017 Mar; 5(2):262-267. PubMed ID: 27813361
[TBL] [Abstract][Full Text] [Related]
5. Sex steroids in serum and prostatic tissue of human cancerous prostate (STERKPROSER trial).
Meunier ME; Neuzillet Y; Raynaud JP; Radulescu C; Ghoneim T; Fiet J; Giton F; Rouanne M; Dreyfus JF; Lebret T; Botto H
Prostate; 2019 Feb; 79(3):272-280. PubMed ID: 30370569
[TBL] [Abstract][Full Text] [Related]
6. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.
Wurzel R; Ray P; Major-Walker K; Shannon J; Rittmaster R
Prostate Cancer Prostatic Dis; 2007; 10(2):149-54. PubMed ID: 17189955
[TBL] [Abstract][Full Text] [Related]
7. Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens.
Monti S; Di Silverio F; Iraci R; Martini C; Lanzara S; Falasca P; Poggi M; Stigliano A; Sciarra F; Toscano V
J Clin Endocrinol Metab; 2001 Apr; 86(4):1700-6. PubMed ID: 11297606
[TBL] [Abstract][Full Text] [Related]
8. Significant association between serum dihydrotestosterone level and prostate volume among Taiwanese men aged 40-79 years.
Liao CH; Li HY; Chung SD; Chiang HS; Yu HJ
Aging Male; 2012 Mar; 15(1):28-33. PubMed ID: 21247242
[TBL] [Abstract][Full Text] [Related]
9. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer.
Heracek J; Hampl R; Hill M; Starka L; Sachova J; Kuncova J; Eis V; Urban M; Mandys V
Steroids; 2007 Apr; 72(4):375-80. PubMed ID: 17368496
[TBL] [Abstract][Full Text] [Related]
10. Effects of steroids on oxytocin secretion by the human prostate in vitro.
Assinder SJ; Nicholson HD
Int J Androl; 2004 Feb; 27(1):12-8. PubMed ID: 14718041
[TBL] [Abstract][Full Text] [Related]
11. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.
Geller J
J Clin Endocrinol Metab; 1990 Dec; 71(6):1552-5. PubMed ID: 1699965
[TBL] [Abstract][Full Text] [Related]
12. Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer.
van der Sluis TM; Meuleman EJ; van Moorselaar RJ; Bui HN; Blankenstein MA; Heijboer AC; Vis AN
BJU Int; 2012 Jan; 109(2):183-8. PubMed ID: 21992404
[TBL] [Abstract][Full Text] [Related]
13. The influence of oestradiol on the metabolism of androgens by human prostatic tissue.
Bard DR; Lasnitzki I
J Endocrinol; 1977 Jul; 74(1):1-9. PubMed ID: 68984
[TBL] [Abstract][Full Text] [Related]
14. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content.
Forti G; Salerno R; Moneti G; Zoppi S; Fiorelli G; Marinoni T; Natali A; Costantini A; Serio M; Martini L
J Clin Endocrinol Metab; 1989 Feb; 68(2):461-8. PubMed ID: 2465302
[TBL] [Abstract][Full Text] [Related]
15. Stable Intraprostatic Dihydrotestosterone in Healthy Medically Castrate Men Treated With Exogenous Testosterone.
Thirumalai A; Cooper LA; Rubinow KB; Amory JK; Lin DW; Wright JL; Marck BT; Matsumoto AM; Page ST
J Clin Endocrinol Metab; 2016 Jul; 101(7):2937-44. PubMed ID: 27172434
[TBL] [Abstract][Full Text] [Related]
16. Prostate tissue androgens: history and current clinical relevance.
Marks LS; Mostaghel EA; Nelson PS
Urology; 2008 Aug; 72(2):247-54. PubMed ID: 18502483
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of MENT on primary cell cultures from benign prostatic hyperplasia and prostate carcinoma.
Mendoza P; Sánchez C; Contreras HR; Vergara J; Acevedo C; Cabezas J; Huidobro C; Noé G; Castellón EA
Int J Androl; 2009 Dec; 32(6):607-15. PubMed ID: 18637152
[TBL] [Abstract][Full Text] [Related]
18. Androgen of the human prostate.
Farnsworth WE; Brown JR
Endocr Res Commun; 1976; 3(2):105-17. PubMed ID: 60232
[TBL] [Abstract][Full Text] [Related]
19. Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man.
Siiteri PK; Wilson JD
J Clin Invest; 1970 Sep; 49(9):1737-45. PubMed ID: 4194768
[TBL] [Abstract][Full Text] [Related]
20. Effects of dutasteride on lower urinary tract symptoms: a prospective analysis based on changes in testosterone/dihydrotestosterone levels and total prostatic volume reduction.
Shigehara K; Miyagi T; Nakashima T; Izumi K; Kitagawa Y; Mizokami A; Koh E; Shimamura M; Namiki M
Aging Male; 2016 Jun; 19(2):128-33. PubMed ID: 26890877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
